Skip to main content

Table 4 Patients’ characteristics according to kidney outcome

From: ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study

Parameter

End stage renal disease

P value

 

No

Yes

 

Patients number

38

13

 

General

   

Gender (% Male)

47

69

0.01

Age (years)

63 [53; 69]

51 [35; 57]

0.01

Vasculitis

 

PR3-ANCA (%)

64

36

0.37

MPO-ANCA (%)

78

22

Severe lung hemorrhage (%)

24

39

0.30

BVAS

15 [13; 21]

16 [15; 21]

0.63

Response to induction therapy

97 %

15 %

<0.0001

Inflammation

 

Hemoglobin (g/dL)

9.0 [7.8; 10.0]

8.0 [6.0; 9.0]

0.07

WBC (per mm3)

9700 [7800; 14200]

8000 [6300; 12500]

0.17

ESR (mm/1 h)

99 [65; 115]

110 [82; 140]

0.28

Fibrinogen (mg/dL)

717 [578; 800]

720 [612; 820]

0.97

Albumin (g/dL)

3.8 [3.2; 4.0]

3.5 [3.1; 3.9]

0.25

Kidney

 

Histopathologic class

   

Crescentic (%)

46

67

0.28

Focal (%)

7

0

Mixed (%)

33

29

Sclerotic (%)

13

5

Creatinine (mg/dL)

4.0 [2.9; 5.8]

9.0 [4.5; 12.0]

0.006

Proteinuria (g/day)

0.6 [0.4; 1.5]

2.3 [1.2; 3.0]

0.007

Hematuria (per mm3)

210 [150; 290]

460 [230; 980]

0.003

Dialysis at presentation (%)

8

62

<0.0001

  1. Values are median [quartile 1; quartile 3] if not otherwise specified
  2. PR3-ANCA patients positive for anti-proteinase 3 antibodies, MPO-ANCA patients positive for anti-myeloperoxidase antibodies, BVAS Birmingham Vasculitis Activity Score, WBC white blood cells, ESR erythrocyte sedimentation rate